Latest Content

Latest Content

Your goal is to improve patients’ lives. Our goal is to make that easier for you.

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

While COVID-19 disrupted business operations, the importance of data integrity in manufacturing has not diminished. How can sponsors reconcile the adaptations they made during the emergency?

Learn More
Loading, please wait

Error - something went wrong!

Let's start a conversation...

Thank you! We'll be in touch soon.
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

David Brown, Global Head of Epidemiology, summarizes the three FDA guidances related to data sources, data standards, and regulatory considerations in RWE/RWD and benefits of early engagement.

Learn More
How to better prepare patients for a cell or gene therapy trial

Parexel spoke with Doug Olson, Cancer survivor and CAR T-cell patient, about how healthcare providers and trial sponsors can better communicate with patients about CGTs.

Read More
Communicating Value to Providers and Payers

Read More
Early planning can help you make the most of expedited regulatory pathways

Read More
Get the eBook
Getting to ‘No’ fast is more important when you are small

Drug development is a complex business. Historically, less than 8% of product candidates are reported to have made it from Phase I to market. One effective way to mitigate risk is to weed out weak...

Learn More
How biotechs can strengthen their value story with advanced analytics

Read five ways biotech companies can enhance their value story with advanced analytics.

Read More
Get the eBook
Want to run a patient-centric rare disease trial? Be site-centric

Patient and site-centricity go hand-in-hand.

Read More
To create more rare disease drugs learn from the past

Read More
Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs

For payment systems to evolve to deal with reimbursement and market access challenges, payers are taking a new look at evidence generation and data usage. Read how pragmatic trials can help >

Learn More
Get the eBook
New endpoints for early-stage cancer are gaining regulatory traction

Read More
Five lessons for building an external control arm that regulators can use

Read More
Episode 17: Funding Biotech Innovation: How to Attract Investors

The biotech industry posted record financing, deals, and M&A numbers in 2020 and 2021, spurred in part by the swift and successful development of COVID-19 vaccines. Despite this favorable funding...

Learn More
How emerging biotechs can enter the Chinese market and prosper

In this article, Parexel experts outline five approaches that foreign companies with limited resources should use to gain a foothold in the Chinese market.

Read More
Get the eBook
Making Expedited Regulatory Pathways Work for Global Drug Development Programs

Article from December 2021 edition of Applied Clinical Trials. Parexel regulatory experts offer top tips for working with regulators on a global scale.

Read More
Biotech Showcase: Fireside Chat with Jamie Macdonald

Parexel CEO, Jamie Macdonald, discusses how the pandemic accelerated and changed the industry, and emerging industry trends driving growth in 2022

Learn More
Three strategies for articulating a coherent product value story

Articulating a coherent product value story from the start of development can help companies attract investors.

Read More
Master Protocol Trials: What Are the Elements of Success?

The shortcomings of traditional study designs have come into sharp relief during the COVID-19 pandemic. Regulatory agencies and the research community alike have responded, acknowledging the need...

Learn More
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

The FDA released a draft guidance that outlines regulatory considerations for INDs that study multiple versions of a cellular or gene therapy (CGT) product in a single trial. There are some...

Learn More
Biosimilar Development: Are therapeutic clinical trials needed?

In this article, Regulatory expert, Cecil Nick, looks at the latest MHRA guidance and what the future holds for biosimilar development.

Learn More
Loading More...